This medicine was designated as an orphan medicine for the treatment of acute lymphoblastic leukaemia in the European Union on 9 December 2022.
This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.
Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:
Autologous T-cells transduced with a lentiviral vector encoding a chimeric antigen receptor against CD7
Treatment of acute lymphoblastic leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
FGK Representative Service GmbH
|March 2023||The sponsorship was transferred from Granzer Regulatory Consulting & Services GmbH, Germany to FGK Representative Service GmbH, Germany.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: